ftInvstr
PAR · Healthcare ₹113.17 +4.99% Mkt Cap ₹140 Cr

PAR

Healthcare Drug Manufacturers - Specialty & Generic
₹113.17
+4.99% today · 30d -3.27%
as of 2026-11-09
Price · Daily Candles
“Revenue slides, profit plunges: PAR battles with quarterly headwinds while PE remains compelling.”
PAR reported a challenging Q4 2026, with revenue dropping -12.18% YoY to ₹20 Cr and net profit collapsing by -48.3% YoY to ₹1 Cr. Despite the quarterly setbacks, the stock trades at a TTM P/E of 8.17, appearing cheap relative to its earnings. Annual revenue growth for FY26 was a modest 2.66% to ₹104 Cr, with net profit declining -1.87% to ₹13 Cr.
BULL CASE
+PAR's TTM P/E of 8.17 is significantly lower than most sector peers like SUNPHARMA (PE 40.41) and DIVISLAB (PE 69.81), suggesting a potentially undervalued position.
+The company's market cap of ₹114 Cr stands at a low 1.05 times its sales, indicating a modest valuation relative to its revenue.
+Promoter holding remains stable at 73.41% as of March 31, 2026, with no QoQ change in the December 2025 to March 2026 period.
BEAR CASE
−Q4 2026 revenue fell by 12.18% YoY to ₹20 Cr, signalling a significant slowdown.
−Net profit in Q4 2026 plummeted by 48.3% YoY to ₹1 Cr, highlighting considerable earnings pressure.
−Operating profit also saw a sharp decline of 44.05% YoY in Q4 2026, with Operating Profit Margin (OPM) contracting by 4.9 percentage points.
−The stock has seen a 1-year return of -12.4% and is trading -24.86% off its 52-week high of ₹122.43.
⟳ What Changed
₹ Latest Earnings · Q ending 2026-09-30
REVENUE
₹27 Cr
-4.28% YoY
NET PROFIT
₹3 Cr
-36.36% YoY
OPM
16.42%
-6.05pp YoY
EPS
₹2.14
PE 8.17
Intrinsic value · DCF: N/A — ML model predicts severe Δ FCF compression (h1=-7.9%, h2=-4.3%, h3=+0.5% of mktcap), driving projected FCF negative by year 3 despite healthy current FCF. Treating as forecast outlier rather than reporting a misleading ₹0 valuation. Use the Strategy Fit and ML sections instead.
◇ Sector Position
PAR's TTM P/E of 8.17 makes it considerably cheaper than peers like SUNPHARMA (40.41 PE) and DIVISLAB (69.81 PE), though its ROE and ROCE figures are not available for direct comparison to their strong 21-27% ROCE.
PEERPEROCE %
PAR8.17—
SUNPHARMA40.4122.46
DIVISLAB69.8121.47
CIPLA29.5225.09
+ 2 more peers — sign in to view
ML Forward Growth Predictions 🔒

9 ML-predicted forward-growth ranks across sales, EBIT, and FCF.

Sign up freeSign in
69
SCORE / 100
Overall
6-axis composite of the sections below.
Performance STRONG 75
Valuation CHEAP 90
Growth MUTED 42
Profitability HIGH 75
Technicals NEUTRAL 62
Risk LOW 70
Key Stats
TTM PE
8.17
P/B
1.07
52W HIGH
₹180.0
OFF HIGH
-37.13%
MKT CAP
₹140 Cr
◉ Active Signals
MACDNeutral0.5694
RSI(14)Neutral49.27
⧉ Strategy Fit 🔒

See which of ftInvstr's 50+ strategies hold PAR and at what entry.

Sign up freeSign in